T cell vaccination in multiple sclerosis: results of a preliminary study |
| |
Authors: | Jingwu Z Zhang Victor M Rivera Maria V Tejada-Simon Deye Yang Jian Hong Sufanfg Li Hani Haykal James Killian Ying C Q Zang |
| |
Institution: | (1) Department of Immunology, Baylor College of Medicine, US;(2) Department of Radiology, The Methodist Hospital, Houston, USA., US;(3) Department of Neurology, Baylor College of Medicine, 6501 Fannin Street, NB302, Houston, TX 77030, USA, Tel.: +1-7 13/7 98-37 90, Fax: +1-7 13/7 98-56 65, US |
| |
Abstract: | Myelin basic protein (MBP)-reactive T cells are potentially involved in the pathogenesis of multiple sclerosis (MS), and
can be depleted by subcutaneous inoculations with irradiated autologous MBP-reactive T cells (T cell vaccination). This preliminary
open label study was undertaken to evaluate whether depletion of MBP-reactive T cells would be clinically beneficial to patients
with MS. Fifty-four patients with relapsing-remitting (RR) MS (n=28) or secondary progressive (SP) MS (n=26) were immunized
with irradiated autologous MBP-reactive T cells and monitored for changes in rate of relapse, expanded disability scale score
(EDSS) and MRI lesion activity over a period of 24 months. Depletion of MBP-reactive T cells correlated with a reduction (40
%) in rate of relapse in RR-MS patients as compared with the pre-treatment rate in the same cohort. However, the reduction
in EDSS was minimal in RR-MS patients while the EDSS was slightly increased in SP-MS patients over a period of 24 months.
Serial semi-quantitative MRI examinations suggest stabilization in lesion activity as compared with baseline MRI. The findings
suggest some potential clinical benefit of T cell vaccination in MS and encourage further investigations to evaluate the treatment
efficacy of T cell vaccination in controlled trials.
Received: 27 November 2000, Received in revised form: 10 May 2001, Accepted: 11 June 2001 |
| |
Keywords: | multiple sclerosis T cell vaccination |
本文献已被 PubMed SpringerLink 等数据库收录! |
|